Skip to main content

Table 2 Factors associated with survival outcomes in patients with uterine corpus endometrial carcinoma

From: LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data

Characteristics

Overall survival

Progression-free survival

N

Univariate analysis

Multivariate analysis

N

Univariate analysis

Multivariate analysis

HR

95% CI

P

Adjusted HR

95% CI

P

HR

95% CI

P

Adjusted HR

95% CI

P

Age, years

 ≥ 63

193

1.456

0.754–2.813

0.263

1.234

0.592–2.570

0.575

157

1.285

0.751–2.197

0.360

1.224

0.676–2.216

0.504

 < 63

177

1 (Ref)

1 (Ref)

177

1 (Ref)

1 (Ref)

Histologic type

 Non-endometrioid

66

2.232

1.146–4.348

0.018

0.887

0.379–2.074

0.782

57

1.987

1.112–3.551

0.020

1.080

0.478–2.442

0.853

 Endometrioid

304

1 (Ref)

1 (Ref)

277

1 (Ref)

1 (Ref)

Grade

 G3

176

3.411

1.661–7.004

0.001

2.016

0.874–4.650

0.100

150

1.539

0.909–2.607

0.109

0.884

0.453–1.724

0.717

 G1,2

194

1 (Ref)

1 (Ref)

184

1 (Ref)

1 (Ref)

FIGO stage

 III-IV

89

4.703

2.474–8.943

< 0.001

3.509

1.734–7.101

< 0.001

72

3.704

2.176–6.307

< 0.001

3.581

1.981–6.473

< 0.001

 I-II

278

1 (Ref)

1 (Ref)

259

1 (Ref)

1 (Ref)

LYL1 amplification

 Yes

22

3.096

1.201–7.982

0.019

1.581

0.541–4.620

0.402

18

2.469

1.055–5.780

0.037

1.652

0.633–4.317

0.305

 No

348

1 (Ref)

1 (Ref)

316

1 (Ref)

1 (Ref)

  1. Abbreviations: HR hazard ratio, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics